Literature DB >> 18684089

Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors.

Thomas E Uveges1, Patricia Collin-Osdoby, Wayne A Cabral, Felicia Ledgard, Leah Goldberg, Clemens Bergwitz, Antonella Forlino, Philip Osdoby, Gloria A Gronowicz, Joan C Marini.   

Abstract

The Brtl mouse, a knock-in model for moderately severe osteogenesis imperfecta (OI), has a G349C substitution in half of type I collagen alpha1(I) chains. We studied the cellular contribution to Brtl bone properties. Brtl cortical and trabecular bone are reduced before and after puberty, with BV/TV decreased 40-45%. Brtl ObS/BS is comparable to wildtype, and Brtl and wildtype marrow generate equivalent number of colony-forming units (CFUs) at both ages. However, OcS/BS is increased in Brtl at both ages (36-45%), as are TRACP(+) cell numbers (57-47%). After puberty, Brtl ObS/BS decreases comparably to wildtype mice, but osteoblast matrix production (MAR) decreases to one half of wildtype values. In contrast, Brtl OcS falls only moderately (approximately 16%), and Brtl TRACP staining remains significantly elevated compared with wildtype. Consequently, Brtl BFR decreases from normal at 2 mo to one half of wildtype values at 6 mo. Immunohistochemistry and real-time RT-PCR show increased RANK, RANKL, and osteoprotegerin (OPG) levels in Brtl, although a normal RANKL/OPG ratio is maintained. TRACP(+) precursors are markedly elevated in Brtl marrow cultures and form more osteoclasts, suggesting that osteoclast increases arise from more RANK-expressing precursors. We conclude that osteoblasts and osteoclasts are unsynchronized in Brtl bone. This cellular imbalance results in declining BFR as Brtl ages, consistent with reduced femoral geometry. The disparity in cellular number and function results from poorly functioning osteoblasts in addition to increased RANK-expressing precursors that respond to normal RANKL/OPG ratios to generate more bone-resorbing osteoclasts. Interruption of the stimulus that increases osteoclast precursors may lead to novel OI therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684089      PMCID: PMC2686922          DOI: 10.1359/jbmr.080804

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  33 in total

1.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

2.  Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.

Authors:  A M Parfitt; M K Drezner; F H Glorieux; J A Kanis; H Malluche; P J Meunier; S M Ott; R R Recker
Journal:  J Bone Miner Res       Date:  1987-12       Impact factor: 6.741

3.  Transgenic mouse model of the mild dominant form of osteogenesis imperfecta.

Authors:  J Bonadio; T L Saunders; E Tsai; S A Goldstein; J Morris-Wiman; L Brinkley; D F Dolan; R A Altschuler; J E Hawkins; J F Bateman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Embryonic lethal mutation in mice induced by retrovirus insertion into the alpha 1(I) collagen gene.

Authors:  A Schnieke; K Harbers; R Jaenisch
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

5.  Retrovirus-induced insertional mutation in Mov13 mice affects collagen I expression in a tissue-specific manner.

Authors:  K Kratochwil; K von der Mark; E J Kollar; R Jaenisch; K Mooslehner; M Schwarz; K Haase; I Gmachl; K Harbers
Journal:  Cell       Date:  1989-06-02       Impact factor: 41.582

6.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.

Authors:  P D Delmas; A Schlemmer; E Gineyts; B Riis; C Christiansen
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

7.  Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength.

Authors:  Kenneth M Kozloff; Angela Carden; Clemens Bergwitz; Antonella Forlino; Thomas E Uveges; Michael D Morris; Joan C Marini; Steven A Goldstein
Journal:  J Bone Miner Res       Date:  2004-01-12       Impact factor: 6.741

8.  Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen.

Authors:  Joan C Marini; Elizabeth Hopkins; Francis H Glorieux; George P Chrousos; James C Reynolds; Caren M Gundberg; C Michael Reing
Journal:  J Bone Miner Res       Date:  2003-02       Impact factor: 6.741

9.  Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-alpha 1(I) collagen gene.

Authors:  A Stacey; J Bateman; T Choi; T Mascara; W Cole; R Jaenisch
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

10.  Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function.

Authors:  C Minkin
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

View more
  35 in total

Review 1.  Chaperoning osteogenesis: new protein-folding disease paradigms.

Authors:  Elena Makareeva; Nydea A Aviles; Sergey Leikin
Journal:  Trends Cell Biol       Date:  2010-12-21       Impact factor: 20.808

2.  Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.

Authors:  A K Oestreich; S M Carleton; X Yao; B A Gentry; C E Raw; M Brown; F M Pfeiffer; Y Wang; C L Phillips
Journal:  Osteoporos Int       Date:  2015-07-16       Impact factor: 4.507

3.  Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine.

Authors:  Haitao Li; Xi Jiang; John Delaney; Tiziana Franceschetti; Ines Bilic-Curcic; Judy Kalinovsky; Joseph A Lorenzo; Danka Grcevic; David W Rowe; Ivo Kalajzic
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

Review 4.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

5.  Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania.

Authors:  Amanda L Scheiber; David K Barton; Basma M Khoury; Joan C Marini; Donald L Swiderski; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2019-11-07       Impact factor: 6.741

6.  Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice.

Authors:  Alison M Muir; Yinshi Ren; Delana Hopkins Butz; Nicholas A Davis; Robert D Blank; David E Birk; Se-Jin Lee; David Rowe; Jian Q Feng; Daniel S Greenspan
Journal:  Hum Mol Genet       Date:  2014-01-12       Impact factor: 6.150

7.  Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta.

Authors:  Mathieu S Davis; Bethany L Kovacic; Joan C Marini; Albert J Shih; Kenneth M Kozloff
Journal:  Bone       Date:  2011-12-20       Impact factor: 4.398

Review 8.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

9.  Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.

Authors:  B P Sinder; L E White; J D Salemi; M S Ominsky; M S Caird; J C Marini; K M Kozloff
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

10.  Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.

Authors:  J A Meganck; D L Begun; J D McElderry; A Swick; K M Kozloff; S A Goldstein; M D Morris; J C Marini; M S Caird
Journal:  Bone       Date:  2013-06-14       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.